Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

This study tests a new type of immune cell therapy called CAR NK cells — engineered natural killer cells from donated cord blood — designed to seek out and destroy specific proteins on B-cell lymphoma cells. This treatment targets CD19 and CD70 proteins found on lymphoma cells that have not responded to prior treatments. **You may be eligible if...** - You are 18 to 75 years old - You have confirmed relapsed or refractory (returned or treatment-resistant) B-cell non-Hodgkin lymphoma (including DLBCL, follicular lymphoma, mantle cell lymphoma, or similar) - You have already tried at least 2 prior lines of treatment (chemotherapy or immunotherapy) - Your cancer continues to grow or returned despite these treatments **You may NOT be eligible if...** - You have never received prior treatment for your lymphoma - You have active lymphoma spread to the brain - You have a serious uncontrolled infection or significant organ dysfunction - You have had a prior stem cell transplant and are not yet recovered Talk to your doctor to see if this trial is right for you.